LRRK2 and Parkinson disease: This led to the hypothesis that all pathogenic mutations would be gain-of-function that cause PD via hyperphosphorylation of substrate proteins, which in turn triggered considerable efforts to develop pharmacological inhibitors of LRRK2 kinase activity.